Research News and Research

RSS

SAEC, Cerner collaborate to identify genetic markers associated with drug-related SAEs

The International Serious Adverse Events Consortium (SAEC) announced today that Cerner Corporation will collaborate with this novel, international research consortium, which is working to identify genetic markers that may help predict which individuals are at risk for a range of serious drug-related adverse events (SAEs). Researchers collaborating with the SAEC will use Cerner Discovere-, Cerner's web-based research platform, to gather data for studies that focus on two SAEs: liver injury and hypersensitivity reactions.

6 May 2010

Experts propose policy solutions to help the U.S. prepare for increasing number of geriatric patients

Leading physician policy experts are calling for changes in medical education policy at multiple levels to ensure that doctors are prepared to treat the country's aging adult population.

6 May 2010

Alcohol consumption during pregnancy can increase risk of AML in children

Although acute myeloid leukemia (AML) is relatively rare in children, drinking alcohol during pregnancy could increase the risk, according to a recent paper published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

6 May 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Pharmacyclics, Inc. today reported financial results for its third quarter ended March 31, 2010.

6 May 2010

Whole body MRI helps physicians diagnose and treat breast cancer: Study

Whole body magnetic resonance imaging should be the imaging modality of choice for the detection of breast cancer metastases (when the cancer has spread beyond the breast) as it is highly accurate and can detect bone metastases while a patient is still asymptomatic (shows no symptoms), according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

6 May 2010

Caffeine is effective in preventing cataract formation, says study

Caffeine may be effective in protecting the lens against damage that could lead to the formation of cataracts, according to a study presented on May 4 at the 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology.

6 May 2010

Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416

Innate Therapeutics today announced funding support from Fast Forward, LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. The award of funds will help support the conduct of a Phase 2A clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.

6 May 2010

Jazz Pharmaceuticals reports 59% increase in first-quarter 2010 revenue

Jazz Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2010 and updated guidance for sales and expenses for 2010.

6 May 2010

Emergent Biosolutions reports decreased revenue in 2010 first quarter

Emergent BioSolutions Inc. announced today its financial results for the first quarter ended March 31, 2010. For the first quarter 2010, total revenues were $46.8 million as compared to $64.5 million in 2009, and net income was $2.5 million, or $0.08 per share, as compared to $11.1 million, or $0.37 per share, in 2009.

6 May 2010

GeoVax Labs reports net loss of $690,789 for first-quarter 2010

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced its financial results for the three months ended March 31, 2010.

6 May 2010

GOP's 'repeal health law' strategy may backfire in general election

Politico reports that several goals of Republicans -- including the repeal of the health care law -- "put them at odds with the majority of voters, according to a new survey by Resurgent Republic," a nonprofit polling and research group established by "GOP operative" Ed Gillespie to assist conservatives and Republicans.

6 May 2010

DexCom first-quarter product revenue up 153%

DexCom, Inc. today reported its unaudited financial results for the quarter ended March 31, 2010.

6 May 2010

Study finds medical homes help lower health care costs, maintain quality

Kaiser Health News: "Some health policy experts and clinicians have long maintained that, in the effort to reduce health care costs and improve patient outcomes, there's no place like (a medical) home. A new study in the May issue of the journal Health Affairs seems to validate that notion. Medical homes — where primary care doctors are held responsible for coordinating care for individual patients - are seen as a model for lowering costs without sacrificing quality.

6 May 2010

Cardiogenesis reports 13% increase in first-quarter 2010 revenue

Cardiogenesis Corporation, a leading developer of surgical products used in the treatment of cardiac patients suffering from severe angina, today reported financial results for its first quarter ended March 31, 2010.

6 May 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Allos Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

New research suggests tPA can act as neuroprotectant against stroke

New research on the properties of the clot-busting stroke drug tPA (tissue-type plasminogen activator) suggests that tPA can act as a neuroprotectant and may form the keystone of an adaptive response to a reduction in blood flow.

6 May 2010

FDA approves Provenge for treating men with advanced prostate cancer

The US Food and Drug Administration has approved a new 'cancer vaccine' for treating men with advanced prostate cancer.

6 May 2010

New test indicates bone marrow cell therapy may benefit MS patients

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Clinipace Worldwide, a global full-service clinical research organization (CRO), announced today that Vaccinogen, a biotechnology company with more than three decades experience researching how to combat cancer using the body's own immune system, has selected the company to manage a pivotal phase 3b confirmatory trial for OncoVAX in the treatment of Stage II Colon Cancer.

6 May 2010